Article
Immunogenicity and protection from malaria infection in BK-SE36 vaccinated volunteers in Uganda is not influenced by HLA-DRB1 alleles.
Parasitology international - 1 Oct 2016
Tougan Takahiro, Ito Kazuya, Palacpac Nirianne Marie Q, Egwang Thomas G, Horii Toshihiro
Abstract excerpt
SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum, is a promising blood stage malaria vaccine candidate. Designated as BK-SE36, the SE36 antigen was formulated with aluminum hydroxyl gel (AHG) and produced under Good Manufacturing Practice (GMP) constraints. In a Phase Ib clinical trial and follow-up study in Uganda, the risk for malaria symptoms was reduced by 72% compared with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
